Vident Advisory’s BioNTech BNTX Stock Holding History

Vident Advisory’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-19,063	Closed	-$2.01M	–	1337
2023 Q4	$2.01M	Buy	19,063 +558	+3%	+$56.2K	0.05%	377
2023 Q3	$2.01M	Buy	+18,505	New	+$2.05M	0.06%	311

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

QOP

Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return

Vident Advisory's BNTX Position: Q1 2024 in Review

Vident Advisory sold out of BioNTech (BNTX) in Q1 2024, closing a stake of 19,063 shares — an estimated $2.01M sold.

Vident Advisory first reported a position in BNTX in Q3 2023 and held it in 2 quarters. The position peaked at $2.01M in Q4 2023. 287 funds tracked by Wall St. Rank hold BNTX as of Q1 2024.

Vident Advisory reported no remaining BioNTech position as of Q1 2024 after selling out during the quarter.
Vident Advisory sold 19,063 BioNTech shares in Q1 2024, an estimated $2.01M.
Vident Advisory first reported a position in BioNTech in Q3 2023 and held it in 2 quarters.
Vident Advisory's BioNTech position peaked at $2.01M in Q4 2023.
287 funds tracked by Wall St. Rank held BioNTech as of Q1 2024.

Based on Vident Advisory's 13F filing for Q1 2024, filed 14 May 2024.